Drugs / AR-12
AR-12
also known as
2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide · OSU-03012 · Pdk1 inhibitor ar-12
Small molecule targets PDPK1 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00978523 | Aug 2009 → Nov 2013 | cancer, lymphoma | Arno Therapeutics | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00978523 ↗ |
| Known as | 2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide | “AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)” NCT00978523 ↗ |
| Known as | OSU-03012 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1650595 ↗ |
| Known as | Pdk1 inhibitor ar-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1650595 ↗ |
| Action | Inhibit | “3-phosphoinositide dependent protein kinase-1 inhibitor” CHEMBL1650595 ↗ |
| Modality | Small molecule | — CHEMBL1650595 ↗ |
| Route | Oral | “Patients will receive orally administered AR-12 once daily” NCT00978523 ↗ |
| Target | PDPK1 | “3-phosphoinositide dependent protein kinase-1 inhibitor” CHEMBL1650595 ↗ |